Basta una iniezione ogni 28 giorni, al Mondino la nuova cura contro l'emicrania - La Provincia Pavese
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label
PDF) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Emicrania da otto anni «Finalmente una cura»
IHC 2019 Late Breaking Abstracts, 2019
Headache & Migraine Archives - Medical Conferences
Does erenumab suspension affect chronic migraine course? A real life experience
Does erenumab suspension affect chronic migraine course? A real life experience
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Does erenumab suspension affect chronic migraine course? A real life experience
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study | The Journal of Headache and Pain | Full Text
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
Does erenumab suspension affect chronic migraine course? A real life experience
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
60th Annual Scientific Meeting American Headache Society® June 28‐July 1, 2018 San Francisco Marriott Marquis San Francisco, CA - 2018 - Headache: The Journal of Head and Face Pain - Wiley Online Library
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
Erenumab Tied to Rapid Conversion From Chronic to Acute Migraine
PDF) Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Full article: A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
